Top practice-changing articles over the last two years.

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• The field of anticoagulation and thromboembolic disease has seen significant advancements since May 2011.
• Critical updates in patient care and outcomes are emerging from recent research.

Purpose of the Study:

• To summarize a "top ten list" of pivotal research papers.
• To identify studies likely to change the management of anticoagulated patients and improve outcomes.

Main Methods:

• Review and synthesis of ten key publications in anticoagulation and thromboembolic disease.
• Analysis of findings related to patient self-management, specific anticoagulant therapies, and secondary prevention strategies.

Main Results:

• Patient self-management of vitamin K antagonists (e.g., warfarin) and self-monitoring reduce thromboembolic events.
• Rivaroxaban demonstrates efficacy in treating pulmonary embolism.
• Apixaban or low-dose aspirin can prevent recurrent venous thromboembolic disease post-therapy.
• Warfarin use post-bioprosthetic aortic valve replacement and its comparison to aspirin in heart failure patients were evaluated.
• Apixaban's risk reduction relative to warfarin varies by CHADS2 score, with greater absolute benefit in high-risk patients.
• Warfarin dose-adjustment algorithms improve therapeutic range and outcomes (RE-LY trial).
• Adding clopidogrel to aspirin for lacunar infarcts did not reduce stroke recurrence but increased bleeding risk.

Conclusions:

• Recent studies offer critical insights into optimizing anticoagulation therapy and managing thromboembolic disorders.
• Evidence supports patient self-management, specific novel oral anticoagulants (NOACs), and tailored secondary prevention strategies.
• Further research is needed to refine treatment protocols and assess long-term outcomes across diverse patient populations.